AI Terminal
Assura PLC
Report Publication Announcement • May 1, 2024
4924_rns_2024-05-01_150d41b1-1dfe-4585-8f66-aca2fae4663e.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6726M
Assura PLC
01 May 2024
1 May 2024
Assura plc
Notice of Year End Results
Assura plc ("the Company"), the UK's leading primary care property investor and developer will announce results for the year ended 31 March 2024 on Tuesday 21 May 2024.
A presentation for analysts and investors, immediately followed by a Q&A with members of the senior management team, can be viewed at 9.00 am BST at the following link:
https://brrmedia.news/AGR_FY23
- Ends -
For more information, please contact:
| Assura plc David Purcell, Investor Relations Director |
Tel: 0161 515 2043 E mail: [email protected] |
| Finsbury Glover Hering Gordon Simpson |
Tel: 0207 251 3801 Email: [email protected] |
Notes to Editors
Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served.
A constituent of the FTSE 250 and the EPRA* indices, as at 30 September 2023, Assura's portfolio was valued at £2.7 billion.
At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026.
Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.
Further information is available at www.assuraplc.com
* EPRA is a registered trademark of the European Public Real Estate Association
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORBUGDSLDXDGSG